Citius Pharmaceuticals Inc CTXR

NAS: CTXR | ISIN: US17322U2078   30/04/2025
0,765 USD (+0,35%)
(+0,35%)   30/04/2025
Grafiek Citius Pharmaceuticals Inc Grafiek Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc in het nieuws

1 april 2025 · Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock · Persbericht

5 september 2024 · Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference · Persbericht

5 september 2024 · Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology · Persbericht

12 augustus 2024 · Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update · Persbericht

12 augustus 2024 · Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc. · Persbericht

12 augustus 2024 · Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments · Persbericht

8 augustus 2024 · Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma · Persbericht

5 augustus 2024 · Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc. · Persbericht

10 juli 2024 · Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates · Persbericht

29 mei 2024 · Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution · Persbericht

Profiel Citius Pharmaceuticals Inc

Farmaceutica
Gezondheidstechnologie
Medicinale en botanische productie
Productie

Website: www.citiuspharma.com

Hoofdzetel: Cranford, New Jersey vlag Verenigde Staten

CEO: Myron Holubiak

Werknemers: 16

Mijn selecties